The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo

被引：0
|
作者：
Haass, N. K. [1 ]
Smalley, K. S. [1 ]
Sproesser, K. [1 ]
Contractor, R. [1 ]
Herlyn, M. [1 ]
机构：
[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
931
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [31] RETRACTED: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib (Retracted Article)
    Song, Hao
    Zhang, Jinna
    Ning, Liang
    Zhang, Honglai
    Chen, Dong
    Pao, Xuelong
    Zhang, Kejun
    MEDICAL SCIENCE MONITOR, 2018, 24 : 3002 - 3010
  • [32] A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Thaker, Premal H.
    Bender, David P.
    Street, Daron
    McGuire, William P.
    Johnston, Carolyn M.
    Rotmensch, Jacob
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 30 - 35
  • [33] Targeted inhibition of the MEK-ERK signaling cascade by the selective MEK1/2 inhibitor AZD6244 (ARRAY-142886) for the treatment of hepatocellular carcinoma.
    Tran, Evelyne
    Soo, Khee Chee
    Chow, Pierce
    Huynh, Hung
    CANCER RESEARCH, 2006, 66 (08)
  • [34] A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)
    Boers-Sonderen, Marye J.
    Desar, Ingrid M.
    Blokx, Willeke
    Timmer-Bonte, Johanna N.
    van Herpen, Carla M.
    ANTI-CANCER DRUGS, 2012, 23 (07) : 761 - 764
  • [35] Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
    Shi, Hubing
    Moriceau, Gatien
    Kong, Xiangju
    Koya, Richard C.
    Nazarian, Ramin
    Pupo, Gulietta M.
    Bacchiocchi, Antonella
    Dahlman, Kimberly B.
    Chmielowski, Bartosz
    Sosman, Jeffrey A.
    Halaban, Ruth
    Kefford, Richard F.
    Long, Georgina V.
    Ribas, Antoni
    Lo, Roger S.
    CANCER DISCOVERY, 2012, 2 (05) : 414 - 424
  • [36] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Bennouna, Jaafar
    Lang, Istvan
    Valladares-Ayerbes, Manuel
    Boer, Katalin
    Adenis, Antoine
    Escudero, Pilar
    Kim, Tae-You
    Pover, Gillian M.
    Morris, Clive D.
    Douillard, Jean-Yves
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
  • [37] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Jaafar Bennouna
    Istvan Lang
    Manuel Valladares-Ayerbes
    Katalin Boer
    Antoine Adenis
    Pilar Escudero
    Tae-You Kim
    Gillian M. Pover
    Clive D. Morris
    Jean-Yves Douillard
    Investigational New Drugs, 2011, 29 : 1021 - 1028
  • [38] The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts
    Shannon, Aoife M.
    Telfer, Brian A.
    Smith, Paul D.
    Babur, Muhammed
    Logie, Armelle
    Wilkinson, Robert W.
    Debray, Camille
    Stratford, Ian J.
    Williams, Kaye J.
    Wedge, Stephen R.
    CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6619 - 6629
  • [39] MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-Dependent Manner in a Mouse Xenograft Model
    Bartholomeusz, Chandra
    Oishi, Tetsuro
    Saso, Hitomi
    Akar, Ugur
    Liu, Ping
    Kondo, Kimie
    Kazansky, Anna
    Krishnamurthy, Savitri
    Lee, Jangsoon
    Esteva, Francisco J.
    Kigawa, Junzo
    Ueno, Naoto T.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (02) : 360 - 369
  • [40] Inhibition of extracellular signal-regulated kinase1/2 mitogen-activated protein kinase (MAPK/ERK1/2) activity by MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma (MM) cell apoptosis and inhibits osteoclasts within the bone marrow (BM) microenvironment
    Tai, Y. T.
    Hideshima, T.
    Song, W.
    Li, X. F.
    Rumizen, M.
    Burger, P.
    Morrison, A.
    Podar, K.
    Schlossman, R.
    Richardson, P.
    Munshi, N. C.
    Ghobrial, I.
    Smith, P.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 147 - 147
12345